ALC earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E 40.57. Updated 2026-07-23.
Alcon (ALC) Research Hub
Alcon (ALC) trades on NYSE, CH in the Healthcare (Medical - Specialties) sector. As of 2026-09-11, shares last closed at 66.03 USD (-3.51%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 40.57, market cap 32.79B. This hub links to the full technical, earnings and options research available for ALC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Specialties) |
|---|---|
| Exchange | NYSE, CH |
| Last close | 66.03 USD (-3.51%) |
| 52-week range | 63.81 USD – 76.2 USD |
| Trend regime | Range |
| 14-day RSI | 33.1 (Bearish) |
| Trailing P/E | 40.57 |
| Market cap | 32.79B |
| Dividend yield | 0.53% |
| Next earnings | 2026-08-10 |
Available research for ALC
Covered Call on ALC: how it works, illustrative setup around the real 66.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALC: how it works, illustrative setup around the real 66.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALC: how it works, illustrative setup around the real 66.03 USD price, max profit/loss, breakeven and when to use it. Educational.
ALC technical analysis: range, last 66.03 USD, RSI 33.1, 52w range 63.81 USD–76.2 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ALC in?
Alcon (ALC) is classified under Healthcare (Medical - Specialties), listed on NYSE, CH.
Is ALC in an uptrend or downtrend?
As of 2026-09-11, ALC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALC's trailing P/E ratio?
ALC's trailing P/E is 40.57, with a market cap of 32.79B. See the earnings research page for full valuation detail.
When does ALC next report earnings?
ALC is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of 0.77 USD.